714 related articles for article (PubMed ID: 23103794)
1. The incretin analogue D-Ala2GIP reduces plaque load, astrogliosis and oxidative stress in an APP/PS1 mouse model of Alzheimer's disease.
Duffy AM; Hölscher C
Neuroscience; 2013 Jan; 228():294-300. PubMed ID: 23103794
[TBL] [Abstract][Full Text] [Related]
2. D-Ala2GIP facilitated synaptic plasticity and reduces plaque load in aged wild type mice and in an Alzheimer's disease mouse model.
Faivre E; Hölscher C
J Alzheimers Dis; 2013; 35(2):267-83. PubMed ID: 23568101
[TBL] [Abstract][Full Text] [Related]
3. Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease.
McClean PL; Hölscher C
Neuropharmacology; 2014 Jan; 76 Pt A():57-67. PubMed ID: 23973293
[TBL] [Abstract][Full Text] [Related]
4. Neuroprotective effects of D-Ala(2)GIP on Alzheimer's disease biomarkers in an APP/PS1 mouse model.
Faivre E; Hölscher C
Alzheimers Res Ther; 2013; 5(2):20. PubMed ID: 23601582
[TBL] [Abstract][Full Text] [Related]
5. Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer's disease.
McClean PL; Hölscher C
Neuropharmacology; 2014 Nov; 86():241-58. PubMed ID: 25107586
[TBL] [Abstract][Full Text] [Related]
6. The effect of focal brain injury on beta-amyloid plaque deposition, inflammation and synapses in the APP/PS1 mouse model of Alzheimer's disease.
Collins JM; King AE; Woodhouse A; Kirkcaldie MT; Vickers JC
Exp Neurol; 2015 May; 267():219-29. PubMed ID: 25747037
[TBL] [Abstract][Full Text] [Related]
7. The incretin hormones glucagonlike peptide 1 and glucose-dependent insulinotropic polypeptide are neuroprotective in mouse models of Alzheimer's disease.
Hölscher C
Alzheimers Dement; 2014 Feb; 10(1 Suppl):S47-54. PubMed ID: 24529525
[TBL] [Abstract][Full Text] [Related]
8. The Novel DA-CH3 Dual Incretin Restores Endoplasmic Reticulum Stress and Autophagy Impairments to Attenuate Alzheimer-Like Pathology and Cognitive Decrements in the APPSWE/PS1ΔE9 Mouse Model.
Panagaki T; Gengler S; Hölscher C
J Alzheimers Dis; 2018; 66(1):195-218. PubMed ID: 30282365
[TBL] [Abstract][Full Text] [Related]
9. Neuroprotective effects of a triple GLP-1/GIP/glucagon receptor agonist in the APP/PS1 transgenic mouse model of Alzheimer's disease.
Tai J; Liu W; Li Y; Li L; Hölscher C
Brain Res; 2018 Jan; 1678():64-74. PubMed ID: 29050859
[TBL] [Abstract][Full Text] [Related]
10. Long-Term Treatment with Liraglutide, a Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist, Has No Effect on β-Amyloid Plaque Load in Two Transgenic APP/PS1 Mouse Models of Alzheimer's Disease.
Hansen HH; Fabricius K; Barkholt P; Kongsbak-Wismann P; Schlumberger C; Jelsing J; Terwel D; Termont A; Pyke C; Knudsen LB; Vrang N
PLoS One; 2016; 11(7):e0158205. PubMed ID: 27421117
[TBL] [Abstract][Full Text] [Related]
11. Val(8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice.
Gengler S; McClean PL; McCurtin R; Gault VA; Hölscher C
Neurobiol Aging; 2012 Feb; 33(2):265-76. PubMed ID: 20359773
[TBL] [Abstract][Full Text] [Related]
12. Cholinergic degeneration is associated with increased plaque deposition and cognitive impairment in APPswe/PS1dE9 mice.
Laursen B; Mørk A; Plath N; Kristiansen U; Bastlund JF
Behav Brain Res; 2013 Mar; 240():146-52. PubMed ID: 23178660
[TBL] [Abstract][Full Text] [Related]
13. Neuroprotective and restorative properties of the GLP-1/GIP dual agonist DA-JC1 compared with a GLP-1 single agonist in Alzheimer's disease.
Salles GN; Calió ML; Hölscher C; Pacheco-Soares C; Porcionatto M; Lobo AO
Neuropharmacology; 2020 Jan; 162():107813. PubMed ID: 31628935
[TBL] [Abstract][Full Text] [Related]
14. The effect of ageing on neurogenesis and oxidative stress in the APP(swe)/PS1(deltaE9) mouse model of Alzheimer's disease.
Hamilton A; Holscher C
Brain Res; 2012 Apr; 1449():83-93. PubMed ID: 22418058
[TBL] [Abstract][Full Text] [Related]
15. Diabetes as a risk factor for Alzheimer's disease: insulin signalling impairment in the brain as an alternative model of Alzheimer's disease.
Hölscher C
Biochem Soc Trans; 2011 Aug; 39(4):891-7. PubMed ID: 21787319
[TBL] [Abstract][Full Text] [Related]
16. Effects of acute and chronic administration of GIP analogues on cognition, synaptic plasticity and neurogenesis in mice.
Faivre E; Hamilton A; Hölscher C
Eur J Pharmacol; 2012 Jan; 674(2-3):294-306. PubMed ID: 22115896
[TBL] [Abstract][Full Text] [Related]
17. Prophylactic liraglutide treatment prevents amyloid plaque deposition, chronic inflammation and memory impairment in APP/PS1 mice.
McClean PL; Jalewa J; Hölscher C
Behav Brain Res; 2015 Oct; 293():96-106. PubMed ID: 26205827
[TBL] [Abstract][Full Text] [Related]
18. Chronic treatment with the α2-adrenoceptor antagonist fluparoxan prevents age-related deficits in spatial working memory in APP×PS1 transgenic mice without altering β-amyloid plaque load or astrocytosis.
Scullion GA; Kendall DA; Marsden CA; Sunter D; Pardon MC
Neuropharmacology; 2011; 60(2-3):223-34. PubMed ID: 20850464
[TBL] [Abstract][Full Text] [Related]
19. Lixisenatide reduces amyloid plaques, neurofibrillary tangles and neuroinflammation in an APP/PS1/tau mouse model of Alzheimer's disease.
Cai HY; Yang JT; Wang ZJ; Zhang J; Yang W; Wu MN; Qi JS
Biochem Biophys Res Commun; 2018 Jan; 495(1):1034-1040. PubMed ID: 29175324
[TBL] [Abstract][Full Text] [Related]
20. Liraglutide and a lipidized analog of prolactin-releasing peptide show neuroprotective effects in a mouse model of β-amyloid pathology.
Holubová M; Hrubá L; Popelová A; Bencze M; Pražienková V; Gengler S; Kratochvílová H; Haluzík M; Železná B; Kuneš J; Hölscher C; Maletínská L
Neuropharmacology; 2019 Jan; 144():377-387. PubMed ID: 30428311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
